Aegera Therapeutics

About Aegera Therapeutics

Aegera Therapeutics Inc. operated as a clinical-stage biotechnology company, focusing on the development of targeted therapeutics for significant unmet medical needs, primarily in oncology and neuropathic pain. Founded in 2000 by Michael Atkin, the Montreal-based company was built upon discoveries made by its founders at the University of Ottawa. The firm's business model revolved around advancing a pipeline of drug candidates through preclinical and early-stage clinical development by leveraging its in-house expertise in medicinal chemistry, biochemistry, and pharmacology.

The company's product pipeline included several programs at various clinical stages. A key asset was AEG35156, a second-generation antisense oligonucleotide designed to inhibit the X-linked Inhibitor of Apoptosis Protein (XIAP). This protein is often over-expressed in cancer cells, contributing to their resistance to apoptosis (programmed cell death). AEG35156 was evaluated in multiple Phase I and Phase II clinical trials for treating solid tumors and leukemias, such as acute myeloid leukemia (AML), both as a standalone therapy and in combination with chemotherapy agents. Another notable candidate was AEG33773, a neuroprotective agent developed for treating peripheral neuropathy, including pain associated with diabetic neuropathy. Over its lifespan, Aegera raised significant capital, securing a total of $37.9 million over five funding rounds from a consortium of investors that included Rosetta Capital, Genechem, Fonds de solidarité FTQ, and BDC Capital.

In a strategic move to broaden its cancer treatment portfolio, Aegera acquired LymphoSign Inc. in 2007, gaining access to LS104, a clinical-stage small-molecule kinase inhibitor. The company's operations concluded on May 27, 2011, when it was acquired by Pharmascience, a large generic pharmaceutical company also based in Quebec. The acquisition was intended to diversify and enhance Pharmascience's research and development activities by continuing Aegera's existing programs. All of Aegera's employees transitioned to Pharmascience as part of the transaction.